CH-EUS in Diagnosis of Inoperable Bile Duct Tumors

Contrast-enhanced Endoscopic Ultrasound in Diagnosis of Inoperable Bile Duct Tumors

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05418543

Enrollment

Registered

2022-06-14

Start date

2022-01-01

Completion date

2022-12-30

Last updated

2022-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bile Duct Cancer, Inoperable Disease

Brief summary

VALIDATION OF THE SUPERIORITY OF CONTRAST ENHANCED ENDOSCOPY TO STANDARD ENDOSCOPY IN THE DIAGNOSIS OF BILE DUCT TUMORS

Interventions

PROCEDUREEndoscopic ultrasound with fine needle biopsy

Patients with unresectable bile duct tumors will be investigated by either CH-EUS with FNA or conventional EUS with FNA

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* Bile duct tumor diagnosed at endoscopic US, CT scan or MRI * INR\<1.5; platelets \> 50.000 * written consent form

Exclusion criteria

* INR\>1.5; platelets \< 50.000 * duodenal invasion or stenosis * patients denial * previous treatment for hepato-biliary tumors

Design outcomes

Primary

Measure	Time frame	Description
CH-EUS FNA has higher diagnostic accuracy for bile tuct tumors	one week	To asses if CH-EUS FNB is superior to CH-EUS FNA when assessing bile duct tumors. To determine the diagnostic accuracy, sensitivity and sensibility.

Countries

Romania

Contacts

Primary ContactRares-Ilie Orzan, PHD student

orzanrares@gmail.com+40727786221

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026